GNRHR and neoplasm: The modification of NIR-II Pdots with the insertion of peptides, such as tumor-specific cetrorelix, forms NIR-II Pdots-GnRH, which target gonadotropin-releasing hormone receptors that are overexpressed in ovarian cancer, heightening affinity towards the tumor cells [73].